Breanna DiAndreth

Breanna DiAndreth

Auto-generated profile, based on publicly available information

Breanna DiAndreth

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
TKTasuku Kitada
Tasuku Kitada
BDBreanna DiAndreth
Breanna DiAndreth
BTBrian Teague
Brian Teague
RWRon Weiss
Ron Weiss
Toward programmed therapeutics: Advances in synthetic biology are enabling the development of new gene and cell therapies. Kitada et al. review recent successes in areas such as cancer immunotherapy and stem cell therapy, point out the limitations of current approaches, and describe prospects for using synthetic biology to overcome these challenges. Broader adoption of these therapies requires precise, context-specific control over cellular behavior. Gene circuits can be built to give sophisticated control over cellular behaviors so that therapeutic functions can, for example, be programmed to activate in response to disease biomarkers. Science , this issue p. eaad1067

10 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RJRoss D. Jones
Ross D. Jones
YQYili Qian
Yili Qian
VSVelia Siciliano
Velia Siciliano
BDBreanna DiAndreth
Breanna DiAndreth
JHJin Huh
Jin Huh
DVDomitilla Del Vecchio
Domitilla Del Vecchio
Synthetic biology has the potential to bring forth advanced genetic devices for applications in healthcare and biotechnology. However, accurately predicting the behavior of engineered genetic devices remains difficult due to lack of modularity, wherein a device’s output does not depend only on its intended inputs but also on its context. One contributor to lack of modularity is loading of transcriptional and translational resources, which can induce coupling among otherwise independently-regulated genes. Here, we quantify the effects of resource loading in engineered mammalian genetic systems and develop an endoribonuclease-based feedforward controller that can adapt the expression level of a gene of interest to significant resource loading in mammalian cells. Near-perfect adaptation to resource loads is facilitated by high production and catalytic rates of the endoribonuclease. Our design is portable across cell lines and enables predictable tuning of controller function. Ultimately, our controller is a general-purpose device for predictable, robust, and context-independent control of gene expression.

14 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVelia Siciliano
Velia Siciliano
BDBreanna DiAndreth
Breanna DiAndreth
BMBlandine Monel
Blandine Monel
JBJacob Beal
Jacob Beal
JHJin Huh
Jin Huh
RWRon Weiss
Ron Weiss
Understanding and reshaping cellular behaviors with synthetic gene networks requires the ability to sense and respond to changes in the intracellular environment. Intracellular proteins are involved in almost all cellular processes, and thus can provide important information about changes in cellular conditions such as infections, mutations, or disease states. Here we report the design of a modular platform for intrabody-based protein sensing-actuation devices with transcriptional output triggered by detection of intracellular proteins in mammalian cells. We demonstrate reporter activation response (fluorescence, apoptotic gene) to proteins involved in hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV) infection, and Huntington’s disease, and show sensor-based interference with HIV-1 downregulation of HLA-I in infected T cells. Our method provides a means to link varying cellular conditions with robust control of cellular behavior for scientific and therapeutic applications.

1 December 2020 in Molecular Immunology
Verified
Journal Article
Open access
AHAgnes E. Hamburger
Agnes E. Hamburger
BDBreanna DiAndreth
Breanna DiAndreth
JCJiajia Cui
Jiajia Cui
MDMark E. Daris
Mark E. Daris
MMMelanie L. Munguia
Melanie L. Munguia
AKAlexander Kamb
Alexander Kamb
We describe an approach to cancer therapy based on exploitation of common losses of genetic material in tumor cells (loss of heterozygosity) (Basilion et al., 1999; Beroukhim et al., 2010). This therapeutic concept addresses the fundamental problem of discrimination between tumor and normal cells and can be applied in principle to the large majority of tumors. It utilizes modular activator/blocker elements that integrate signals related to the presence and absence of ligands displayed on the cell surface (Fedorov et al., 2013). We show that the targeting system works robustly in vitro and in a mouse cancer model where absence of the HLA-A*02 allele releases a brake on engineered T cells activated by the CD19 surface antigen. This therapeutic approach potentially opens a route toward a large, new source of cancer targets.

2 August 2019 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JGJeremy J Gam
Jeremy J Gam
BDBreanna DiAndreth
Breanna DiAndreth
RJRoss D Jones
Ross D Jones
JHJin Huh
Jin Huh
RWRon Weiss
Ron Weiss
Biological research is relying on increasingly complex genetic systems and circuits to perform sophisticated operations in living cells. Performing these operations often requires simultaneous delivery of many genes, and optimizing the stoichiometry of these genes can yield drastic improvements in performance. However, sufficiently sampling the large design space of gene expression stoichiometries in mammalian cells using current methods is cumbersome, complex, or expensive. We present a ‘poly-transfection’ method as a simple yet high-throughput alternative that enables comprehensive evaluation of genetic systems in a single, readily-prepared transfection sample. Each cell in a poly-transfection represents an independent measurement at a distinct gene expression stoichiometry, fully leveraging the single-cell nature of transfection experiments. We first benchmark poly-transfection against co-transfection, showing that titration curves for commonly-used regulators agree between the two methods. We then use poly-transfections to efficiently generate new insights, for example in CRISPRa and synthetic miRNA systems. Finally, we use poly-transfection to rapidly engineer a difficult-to-optimize miRNA-based cell classifier for discriminating cancerous cells. One-pot evaluation enabled by poly-transfection accelerates and simplifies the design of genetic systems, providing a new high-information strategy for interrogating biology.

11 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
BDBreanna DiAndreth
Breanna DiAndreth
NWNoreen Wauford
Noreen Wauford
EHEileen Hu
Eileen Hu
SPSebastian Palacios
Sebastian Palacios
RWRon Weiss
Ron Weiss
Regulated transgene expression is an integral component of gene therapies, cell therapies and biomanufacturing. However, transcription factor-based regulation, upon which most applications are based, suffers from complications such as epigenetic silencing that limit expression longevity and reliability. Constitutive transgene transcription paired with post-transcriptional gene regulation could combat silencing, but few such RNA- or protein-level platforms exist. Here we develop an RNA-regulation platform we call “PERSIST" which consists of nine CRISPR-specific endoRNases as RNA-level activators and repressors as well as modular OFF- and ON-switch regulatory motifs. We show that PERSIST-regulated transgenes exhibit strong OFF and ON responses, resist silencing for at least two months, and can be readily layered to construct cascades, logic functions, switches and other sophisticated circuit topologies. The orthogonal, modular and composable nature of this platform as well as the ease in constructing robust and predictable gene circuits promises myriad applications in gene and cell therapies.